This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Beyond Biotech, 5 ETFs Up At Least 10% in Q4
by Sanghamitra Saha
Apart from biotech, these ETFs are seeing solid momentum in the ongoing quarter.
Why Biotech ETFs are Surging to New Highs
by Neena Mishra
increasing M&A deals and cutting edge therapies are driving biotech ETFs higher
Biotech ETFs Hit New Highs on Deal Activities
by Sweta Killa
Following the new deals in the healthcare space, a few biotech ETFs hit new highs.
A Guide to Biotech ETF Investing
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to work in favor of the biotech market.
Russell 2000 Hits New 1-Year High: 5 Best-Performing ETFs
by Sweta Killa
Small caps started to show their momentum and are trying to catch up with the large cap peers. The Russell 2000 Index hit a new 52-week high.
5 ETFs That Deserve Special Thanks in 2019
by Sweta Killa
These ETFs deserve special thanks and attention going into the New Year.
Healthcare Sector Outperforming: 5 Best ETFs & Stocks QTD
by Sweta Killa
Healthcare bounced back with an outperformance starting the fourth quarter.
The Zacks Analyst Blog Highlights: SEA, SBIO, WOOD, CRAK and FTXL
by Zacks Equity Research
The Zacks Analyst Blog Highlights: SEA, SBIO, WOOD, CRAK and FTXL
5 Best Sector ETFs of October With Double-Digit Returns
by Sweta Killa
October has been kind to the U.S. stock market thanks to U.S.-China trade progress, better-than-expected corporate earnings and a third Fed rate cut.
Healthcare ETFs Win in October: Here's Why
by Sweta Killa
The healthcare sector, which has been the second-worst performer among the 11 major S&P 500 sectors this year, took the center stage this month with some outperformance compared to other sectors.
Navigating The Healthcare Industry: Science Fiction Turns to Reality
by Panel Of Zacks Experts
Kevin Cook joins us to help walk us through the maze that is the healthcare industry. We touch on everything from the hottest trends all the way down to how to pick a winning stock!
Biotech ETFs Surge on a Flurry of Positive News
by Sweta Killa
The biotech sector got a boost over the past week from a flurry of positive news including trial results and deal activities.
Top-Performing Biotech ETFs YTD
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to boost the biotech stocks. Accordingly, we take a look at biotech ETFs gaining more than 10% year to date.
Why These Innovative Biotech ETFs Are Soaring
by Neena Mishra
Strong M&A activity has sent shares of many small, innovative biotech companies surging
Pfizer-Array Biopharma Deal Bump Up Biotech ETFs
by Sweta Killa
Pfizer struck a deal to acquire the cancer drugmaker Array Biopharma for $11 billion in an all-cash consideration.
Markets & ETFs Digest Trade Spat: Is It a Dead-Cat-Bounce?
by Sanghamitra Saha
Though markets rallied probably on the undervalued status and a still-steady US economy, rising recessionary fears and full-scale trade war risks should brighten the appeal of safer ETFs.
Biotechnology Market on a Tear: 5 ETFs in Spotlight
by Sweta Jaiswal, FRM
Increasing M&A deals, growing AI dominance and favorable regulatory tidings continue to accelerate the biotech market. Accordingly, ETFs with exposure to the sector continue to shine.
Top ETF Stories of February
by Sanghamitra Saha
Inside the top ETF events of the month of February.
Biotech ETFs Jump on Roche-Spark Deal
by Sweta Killa
The news of Roche-Spark Deal has triggered speculations of merger wave in the gene therapy industry and pushed the biotech ETFs higher.
The Zacks Analyst Blog Highlights: SBIO, ISMD, JKL, JSML and JKK
by Zacks Equity Research
The Zacks Analyst Blog Highlights: SBIO, ISMD, JKL, JSML and JKK
Small Caps Taking Charge of the Bulls: 6 ETF Winners YTD
by Sweta Killa
we have presented six top performing small-cap ETFs of the current rally that have gained in double digits and will continue their outperformance.
Top ETFs of Last Week
by Sanghamitra Saha
These ETFs have had a strong last week.
6 Wining ETF Areas From a Late Santa Rally
by Sanghamitra Saha
These sector ETFs have made the most of the start of this Santa Rally.
Sarepta Pharma Pushes Two Biotech ETFs to New Highs
by Sweta Killa
The encouraging early trial results for a gene therapy for Duchenne muscular dystrophy pushed Sarepta Therapeutics and few biotech ETFs to new highs.
5 Small-Cap ETFs & Stocks Crushing Russell 2000
by Sweta Killa
We have presented five ETFs & stocks that have easily crushed the Russell 2000 index this year and are likely to continue their strong performance.